Gov. Murphy says Johnson & Johnson’s one-dose vaccine would be ‘game-changer’

The vaccine wouldn't require a second dose, doesn't need hyper-cold storage

Johnson & Johnson’s one-dose COVID-19 vaccine is in its third phase of a clinical trial with 45,000 enrollees. The reported results so far are promising, and the potential impact game-changing. Senior Correspondent Brenda Flanagan explains why.